– Quris-AI, a leading Bio-AI company revolutionizing drug development, has acquired Nortis, a pioneer in microphysiology systems (MPS) technology, formerly known as Numa Biosciences.

–Quris AI是一家革新药物开发的领先生物人工智能公司，收购了微生理系统（MPS）技术的先驱Nortis，以前称为Numa Biosciences。

– The strategic acquisition will integrate Nortis’s advanced Kidney-on-Chip technology into Quris-AI’s Bio-AI platform, enhancing its ability to predict drug safety and efficacy in humans.

–这项战略收购将诺蒂斯先进的芯片上肾脏技术整合到Quris AI的生物人工智能平台中，增强其预测药物安全性和人体疗效的能力。

Combining Cutting-Edge Technologies

结合尖端技术

Nortis’s Kidney-on-Chip models have been validated by the National Center for Advancing Translational Sciences (NCATS) and represent a significant advancement in in-vitro drug testing and personalized medicine. By combining this technology with Quris-AI’s machine learning models and patented patient-on-chip system, the company aims to improve the accuracy and efficiency of drug development..

诺蒂斯的肾芯片模型已经过国家转化科学促进中心（NCATS）的验证，代表了体外药物测试和个性化医学的重大进步。通过将该技术与Quris AI的机器学习模型和获得专利的患者芯片系统相结合，该公司旨在提高药物开发的准确性和效率。

Quris-AI’s Bio-AI Platform: Revolutionizing Drug Development

Quris AI的生物人工智能平台：彻底改变药物开发

Quris-AI’s Bio-AI Clinical Prediction Platform is transforming the drug development process by simulating clinical trials and predicting drug responses in humans. This approach reduces the reliance on traditional animal testing and accelerates the identification of promising drug candidates.

Quris AI的生物AI临床预测平台正在通过模拟临床试验和预测人类的药物反应来改变药物开发过程。这种方法减少了对传统动物试验的依赖，并加速了有希望的候选药物的鉴定。

The acquisition of Nortis will enable Quris-AI to:

收购Nortis将使Quris AI能够：

Enhance its Bio-AI Platform: Integrate Nortis’s Kidney-on-Chip technology to improve the accuracy of drug safety and efficacy predictions.Advance Drug Development: Accelerate the development of new drugs by identifying and eliminating potentially harmful candidates earlier in the process.Expand Research Collaborations: Continue Nortis’s collaborations with research institutes, the FDA, and pharmaceutical companies to advance kidney disease research.Improve Drug Safety Prediction: Strengthen Quris-AI’s capabilities in predicting drug safety and efficacy in humans..

增强其生物人工智能平台：整合Nortis的片上肾脏技术，以提高药物安全性和疗效预测的准确性。推进药物开发：通过在过程的早期识别和消除潜在有害的候选药物，加速新药的开发。扩大研究合作：继续与研究机构、FDA和制药公司合作，推进肾脏疾病研究。改进药物安全性预测：加强Quris AI预测药物安全性和人体疗效的能力。

“We are thrilled to incorporate Nortis’s pioneering technology into the Quris-AI platform,” said Dr. Isaac Bentwich, Founder and CEO of Quris-AI. “This acquisition represents a powerful synergy between Nortis’s legacy of scientific excellence and Quris’s cutting-edge Bio-AI capabilities to significantly enhance the accuracy of drug safety predictions in both pre-clinical and clinical phases.

Quris AI创始人兼首席执行官Isaac Bentwich博士表示：“我们很高兴将Nortis的开创性技术纳入Quris AI平台。此次收购代表了Nortis的卓越科学遗产与Quris的尖端生物AI能力之间的强大协同作用，可显着提高临床前和临床阶段药物安全预测的准确性。

We are dedicated to continuing to push the boundaries of drug safety prediction and personalized medicine, ultimately leading to better patient outcomes and advancing the future of healthcare.”.

我们致力于继续推动药物安全预测和个性化医疗的界限，最终导致更好的患者结果并推动医疗保健的未来。”